| # | Title | Journal | Year | Citations |
|---|
| 1 | Benzodiazepine use, misuse, and abuse: A review | Mental Health Clinician | 2016 | 115 |
| 2 | Major depressive disorder in children and adolescents | Mental Health Clinician | 2018 | 96 |
| 3 | Essential oil of lavender in anxiety disorders: Ready for prime time? | Mental Health Clinician | 2017 | 71 |
| 4 | Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review | Mental Health Clinician | 2016 | 60 |
| 5 | Review of the many faces of synthetic cannabinoid toxicities | Mental Health Clinician | 2019 | 50 |
| 6 | Role of antidepressants in the treatment of adults with anorexia nervosa | Mental Health Clinician | 2018 | 46 |
| 7 | Dialectical behavior therapy as treatment for borderline personality disorder | Mental Health Clinician | 2016 | 39 |
| 8 | Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature | Mental Health Clinician | 2017 | 39 |
| 9 | Valproic acid–induced hyperammonemia: Incidence, clinical significance, and treatment management | Mental Health Clinician | 2018 | 37 |
| 10 | Clinical potential of psilocybin as a treatment for mental health conditions | Mental Health Clinician | 2017 | 36 |
| 11 | Pharmacokinetic characteristics of antiepileptic drugs (AEDs) | Mental Health Clinician | 2016 | 36 |
| 12 | Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis | Mental Health Clinician | 2018 | 35 |
| 13 | The effects of ketamine on suicidality across various formulations and study settings | Mental Health Clinician | 2019 | 35 |
| 14 | Improving medication-related outcomes for patients with psychiatric and neurologic disorders: Value of psychiatric pharmacists as part of the health care team | Mental Health Clinician | 2015 | 34 |
| 15 | Management of antipsychotic-induced hyperprolactinemia | Mental Health Clinician | 2016 | 32 |
| 16 | What's new in multiple sclerosis? | Mental Health Clinician | 2017 | 30 |
| 17 | Antidepressants and suicidality: History, the black-box warning, consequences, and current evidence | Mental Health Clinician | 2015 | 30 |
| 18 | Treatment of psychotic symptoms in patients with Parkinson disease | Mental Health Clinician | 2017 | 28 |
| 19 | Review of cariprazine in management of psychiatric illness | Mental Health Clinician | 2017 | 28 |
| 20 | Management of serious cardiac adverse effects of antipsychotic medications | Mental Health Clinician | 2017 | 28 |
| 21 | Evaluation of adherence and persistence with oral versus long-acting injectable antipsychotics in patients with early psychosis | Mental Health Clinician | 2018 | 28 |
| 22 | A review of suicide risk assessment instruments and approaches | Mental Health Clinician | 2015 | 27 |
| 23 | Impact of a mental health clinical pharmacist on a primary care mental health integration team | Mental Health Clinician | 2017 | 27 |
| 24 | Impact of pharmacists on outcomes for patients with psychiatric or neurologic disorders | Mental Health Clinician | 2020 | 27 |
| 25 | Drug-induced cognitive impairment: Effect of cardiovascular agents | Mental Health Clinician | 2016 | 26 |
| 26 | Brain-derived neurotrophic factor and schizophrenia | Mental Health Clinician | 2016 | 26 |
| 27 | Treatment of posttraumatic stress disorder: Focus on pharmacotherapy | Mental Health Clinician | 2019 | 25 |
| 28 | A review of medical marijuana for the treatment of posttraumatic stress disorder: Real symptom re-leaf or just high hopes? | Mental Health Clinician | 2018 | 24 |
| 29 | Surveys of substance use disorders education in US pharmacy programs | Mental Health Clinician | 2018 | 22 |
| 30 | A review of the clinical utility of serum clozapine and norclozapine levels | Mental Health Clinician | 2015 | 21 |
| 31 | Dysphagia with second-generation antipsychotics: A case report and review of the literature | Mental Health Clinician | 2017 | 21 |
| 32 | Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder | Mental Health Clinician | 2017 | 21 |
| 33 | Overview of pharmacogenomic testing in clinical practice | Mental Health Clinician | 2018 | 21 |
| 34 | Pharmacists' attitudes, interest, and perceived skills regarding suicide prevention | Mental Health Clinician | 2019 | 21 |
| 35 | Evidence for the use of “medical marijuana” in psychiatric and neurologic disorders | Mental Health Clinician | 2017 | 20 |
| 36 | Antimicrobial-induced cognitive side effects | Mental Health Clinician | 2016 | 19 |
| 37 | Atypical antipsychotics: A review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects | Mental Health Clinician | 2016 | 19 |
| 38 | A survey of pharmacists' perceptions of the adequacy of their training for addressing mental health–related medication issues | Mental Health Clinician | 2017 | 19 |
| 39 | Review of antidepressants in the treatment of neuropathic pain | Mental Health Clinician | 2015 | 19 |
| 40 | D-cycloserine in the treatment of posttraumatic stress disorder | Mental Health Clinician | 2017 | 19 |
| 41 | Changing student attitudes and perceptions toward opioid use disorder | Mental Health Clinician | 2018 | 19 |
| 42 | Impact of a clinical pharmacist–managed clinic in primary care mental health integration at a Veterans Affairs health system | Mental Health Clinician | 2018 | 18 |
| 43 | Flubromazolam overdose: A review of a new designer benzodiazepine and the role of flumazenil | Mental Health Clinician | 2019 | 18 |
| 44 | Medical mimics: Differential diagnostic considerations for psychiatric symptoms | Mental Health Clinician | 2016 | 17 |
| 45 | Quantitative and economic analysis of clinical pharmacist interventions during rounds in an acute care psychiatric hospital | Mental Health Clinician | 2016 | 16 |
| 46 | Coadministration of intramuscular olanzapine and benzodiazepines in agitated patients with mental illness | Mental Health Clinician | 2018 | 16 |
| 47 | Using pharmacogenomics and therapeutic drug monitoring to guide drug selection and dosing in outpatient mental health comprehensive medication management | Mental Health Clinician | 2020 | 16 |
| 48 | Cannabidiol in epilepsy: The indications and beyond | Mental Health Clinician | 2020 | 16 |
| 49 | Impact on an integrated psychiatric pharmacy service in a primary care clinic | Mental Health Clinician | 2019 | 16 |
| 50 | Management of treatment-resistant generalized anxiety disorder | Mental Health Clinician | 2020 | 16 |
